Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study

被引：5
|
作者：
Cruickshank, JM [1 ]
机构：
[1] Oxonian Cardiovasc Consultancy, Long Melford CO10 9DE, Suffolk, England
来源：
LANCET | 2002年 / 359卷 / 9324期
关键词：
D O I：
10.1016/S0140-6736(02)09071-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2200 / 2201
页数：2
相关论文
共 50 条
  • [21] Albuminuria predicts cardiovascular outcome with losartan versus atenolol in patients with diabetes, hypertension and left ventricular hypertrophy. A life diabetes substudy
    Ibsen, H
    Olsen, MH
    Wachtell, K
    Borch-Johnsen, K
    Lindholm, L
    Dahloef, B
    Snapinn, S
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (05) : 2A - 2A
  • [22] Albuminuria predicts cardiovascular outcome on treatment with losartan versus atenolol in patients with diabetes, hypertension and left ventricular hypertrophy?: A life diabetes substudy
    Ibsen, H
    Olsen, MH
    Wachtell, K
    Borch-Johnsen, K
    Lindholm, L
    Dahlöf, B
    Snapinn, S
    [J]. JOURNAL OF HYPERTENSION, 2004, 22 : S64 - S64
  • [23] A study of the quality of life of hemodialysis patients with and without diabetes mellitus
    Falakidou, S.
    Kafkia, T.
    Kourakos, M.
    Roundenko, I.
    Spaia, S.
    Dimitriadou, A.
    Minasidou, E.
    [J]. ARCHIVES OF HELLENIC MEDICINE, 2018, 35 (03): : 364 - 371
  • [24] Differential vascular effects of aspirin in patients with type 2 diabetes without cardiovascular disease and matched controls without diabetes
    Vernstrom, L.
    Laugesen, E.
    Grove, E. L.
    Baier, J. M.
    Gullaksen, S.
    Hvas, A. -M.
    Poulsen, P. L.
    Funck, K. L.
    [J]. DIABETOLOGIA, 2019, 62 : S558 - S558
  • [25] Quality of life in patients with NIDDM and renal disease at baseline: The losartan renal protection study
    Davies, GM
    Dasbach, EJ
    Shahinfar, S
    Simpson, R
    Haffner, SM
    [J]. DIABETES, 2001, 50 : A217 - A217
  • [26] Effects of losartan on cardiovascular outcomes in patients with type 2 diabetes and nephropathy - The reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study
    Kowey, P
    Haffner, S
    Dickson, T
    Zhang, ZX
    Shahinfar, S
    Brenner, BM
    [J]. CIRCULATION, 2002, 106 (19) : 507 - 508
  • [27] Estimation of cardiovascular risk and detection of subclinical carotid atheromatosis in patients with diabetes without a history of cardiovascular disease
    Masson, Walter
    De Francesca, Salvador
    Molinero, Micaela
    Siniawski, Daniel
    Mulassi, Andres
    Espinoza Morales, Frank
    Huerin, Melina
    Lobo, Martin
    Molinero, Graciela
    [J]. ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2017, 61 (02): : 122 - 129
  • [28] The visceral adiposity index predicts cardiovascular events both in cardiovascular disease patients with and in those without diabetes
    Saely, Christoph H.
    Vonbank, Alexander
    Heinzle, Christine
    Zanolin, Daniela
    Larcher, Barbara
    Mader, Arthur
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 : 359 - 359
  • [29] The Visceral Adiposity Index Predicts Cardiovascular Events Both in Cardiovascular Disease Patients With and in Those Without Diabetes
    Saely, Christoph H.
    Vonbank, Alexander
    Heinzle, Christine
    Zanolin, Daniela
    Larcher, Barbara
    Mader, Arthur
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    [J]. DIABETES, 2018, 67
  • [30] The visceral adiposity index predicts cardiovascular events both in cardiovascular disease patients with and in those without diabetes
    Saely, C. H.
    Vonbank, A.
    Heinzle, C.
    Zanolin, D.
    Larcher, B.
    Mader, A.
    Leiherer, A.
    Muendlein, A.
    Drexel, H.
    [J]. DIABETOLOGIA, 2018, 61 : S548 - S549
12345